Portal hypertension. Update on pathophysiology and management.
A lot has been learned about the pathophysiology of portal hypertension and its complications. This knowledge has led to vast advancements in therapy for this serious disease. I believe the future will carry more breakthroughs in therapy intercepting earlier steps in the disease process such as arresting fibrogenesis, inducing fibrinolysis or possibly targeting vascular remodeling and neovessel formation or employing hepatocytes transplantation.
Chatila
R
R
Division of Gastroenterology, Makassed General Hospital, PO Box 116031, Beirut, Lebanon. chatilarajaa@hotmail.com
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000628:therapy; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D008102:Liver Circulation / Q000187:drug effects; D009569:Nitric Oxide / Q000378:metabolism*; D013148:Spironolactone / Q000627:therapeutic use; D013152:Splanchnic Circulation / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D006490:Hemostatics; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D013148:Spironolactone; D009569:Nitric Oxide